The engineer’s perspective: evolution in cell therapy bioprocess automation

Cell & Gene Therapy Insights 2020; 6(11), 1615–1621


Published: 23 December 2020
Brijender Parsad

Brijender Parsad has been involved with process control and automation field for over 25 years. Currently he is a Senior Manager, Corporate Engineering Group for Kite, a Gilead Company. Kite is singularly focused on cell therapy — the use of genetically modified immune cells programmed to target tumors. Previously he worked for Novartis, Dupont, Georgia Pacific and as a consultant in automation engineering for chemical, biotech and pharma industries.